Meta Materials Announces Premiere – GuruFocus.com
Foundational patent covers anti-reflective metamaterial films and system architecture
HALIFAX, N.S. / ACCESSWIRE / May 13, 2022 / Meta Materials Inc. (the “Company” or “META®”) (NASDAQ: MMAT), (FSE: MMAT), a developer of high performance functional materials and nanocomposites, today announced that the UK-owned subsidiary proprietary to the Company, Medical Wireless Sensing (“MediWise”), was granted the first U.S. patent (United States 11,298,052 B2) for its glucoWISE® non-invasive glucose sensing system and associated anti-reflective metamaterial films. This foundational patent covers anti-reflective metamaterial films, which improve signal penetration through the skin, and different configurations of the detection system to collect biomarker readings at various locations on the body. The co-inventors are Dr. Georgios “George” Palikaras, Dr. Efthymios “Themos” Kallos and Dr. Helena Cano-Garcia.
“The granting of this patent in the United States is a key step in our development plan for glucoWISE®,” said Dr. Themos Kallos, co-founder and chief scientific officer of META. “This is our foundational patent on non-invasive biosensing using radio waves, built around the central idea of an ultra-thin metamaterial film that acts as an anti-reflective coating for the skin, resulting in increased signal penetration into tissues. It paves the way for a totally painless radio wave-based glucose sensing system in the United States, which is currently home to more than 30 million people with diabetes. »
Lead Inventor Dr Cano-Garcia at the MediWise facility in London, UK
Example of broadband metamaterial film
The glucoWISE® system under development is intended to allow blood glucose monitoring without the need for painful finger pricks. META plans to first introduce a tabletop version of the device, for use at home or in the clinic, followed by a handheld portable version to enable quick and painless monitoring anywhere, and thereafter , a portable version. In July 2021, META announced the completion of a 27-month UK-funded project to develop a non-invasive glucose sensing prototype, which for the first time combined radio waves and optical sensors to improve the accuracy of predicting changes in glucose levels . The development team has since grown and is actively working on the next-generation prototype, suitable for human studies in 2022.
“META’s large and rapidly growing intellectual property portfolio is a key part of our strategy to sustain growth and establish a sustainable competitive advantage,” said George Palikaras, President and CEO. “Dr. Shann Kerner joined us last September as Director of Intellectual Property. Under his leadership, we have just achieved a key milestone, with 302 active utility and design patent documents, more than double the 149 we announced in the second quarter report in August 2021.”
META patent portfolio includes 175 issued patents, including one design patent, and 127 pending patent applications, in 81 patent families, 48 of which include at least one issued patent. There are 15 active patent documents for glucoWISE®, including 5 issued patents, in 6 patent families, 3 of which include at least one issued patent.
About Meta Materials Inc.
META® delivers previously unattainable performance, in a range of applications, by inventing, designing, developing and manufacturing durable and highly functional materials. Our extensive technology platform enables leading global brands to deliver breakthrough products to their customers in consumer electronics, 5G communications, health and wellness, aerospace, automotive and clean energy. Our nano-optical technology provides anti-counterfeiting security features for government documents and currencies and authentication for brands. Our achievements have been widely recognized, including being named Lux Research Innovator of the Year in 2021. To learn more, visit www.metamaterial.com.
This press release contains forward-looking information or statements within the meaning of Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, relating to the Company, which may include, but are not limited to, statements regarding business strategies, product development, expansion plans and the operational activities of the Company. Often, but not always, forward-looking information can be identified by the use of words such as “pursuing”, “potential”, “predicted”, “projects”, “research”, “plans”, “expects”. , “intends”, “plans”, “believes” or variations (including negative variations) of these words and phrases, or statements that certain actions, events or results “could”, “might”, “should”, “would” or “will” be taken, occur or be carried out. These statements are based on the Company’s management’s current expectations and outlook of future events and are based on assumptions and subject to risks and uncertainties. Although the Company’s management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and may differ materially due to known and unknown risk factors and uncertainties affecting the Company, the capabilities of our facilities and their expansion, research and development projects of the Company, the market potential of the Company’s products, the Company’s market position, the scalability of the Company’s production capacity, the ability to engage new customers, the timing of the selection programs of materials, the ability to reduce production costs, improve metamaterials manufacturing capabilities and expand market reach into new applications and industries, the ability to accelerate time-to-market plans, the possibility of new contracts customers, the ongoing commitment of our employees, the technology industry, strategic and operational market activities and the ability management to manage and operate the business. Further details of these and other risks that may affect the Company’s business are described under the heading “Forward-Looking Information” and under the heading “Risk Factors” in the Company’s Form 10-K. filed with the SEC on March 1, 2022, with an SEC filing date of March 2, in the Company’s Form 10-Q filed with the SEC on May 10, 2022, and in subsequent filings by Meta Materials with the SEC, which are available on the SEC’s website at www.sec.gov. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in the forward-looking statements, there may be other factors that cause the actions, events or results differ from those anticipated, estimated or expected. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether whether as a result of new information, future events, or otherwise, except to the extent required by law.
Vice President, Corporate Development and Communications
Meta Materials Inc.
Senior Vice President
E-mail: [email protected]
THE SOURCE: Meta Materials Inc.
See the source version on accesswire.com: